In Development-Stage Biotechs, Success Comes Down to One Asset:
Expert Analyst Boris Peaker Discusses the Competitive
Biotechnology Environment with The Wall Street Transcript  Wall
Street Transcript    Companies include: Celgene Corporation
(CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX),
Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc.
(PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc.
(IMGN) and many more.   TWST: What is the competitive
environment like for the kinds of companies you cover? And what
gives a company a competitive advantage in your mind, especially
since a lot of them are development-stage and not yet
profitable?  Mr. Peaker: There are certainly obviously a number
of factors that give companies competitive advantages. But I
think as you've outlined, in a development-stage biotech where
basically most of these companies are driven by a single drug,
some of them maybe two drugs, but for the most part it comes
down to just one asset. You can have the greatest